moneyheap
TGTX +7.10% on Nov 10 · Analysis updated Nov 10, 2026, 10:34 AM ET
Why is TG Therapeutics, Inc. (TGTX) stock up?
TG Therapeutics reported third-quarter revenue of $259.9 million on Monday, up about 61% from a year earlier and above the roughly $245.5 million analysts expected, driven by its multiple sclerosis drug BRIUMVI. It raised its 2026 global revenue target to about $1 billion, ahead of a consensus near $960 million. Adjusted earnings of $0.35 a share were a few cents below some estimates, partly because last year's figure included a one-time tax benefit. The stock rose about 6% on Monday on roughly twice its usual volume and was up another 7.1% to $67.88 at about 10:25 AM ET, at a 52-week high.
News behind the analysis
- TG Therapeutics stock hits 52-week high at 63.68 USDQ3 revenue $259.94 million versus $245.47 million expected, up 61%; adjusted EPS $0.35 versus $0.37; full-year revenue outlook raised.
- 55,186 TG Therapeutics, Inc. $TGTX Shares Sold by Penn Capital Management Company LLCRecaps the Nov. 9 report: revenue up 60.8% to $259.9 million versus about $245.5 million expected; analysts expect $0.92 EPS this year.
- TG Therapeutics stock quote and newsNews feed: TG raises FY26 revenue target to $1 billion versus $960 million consensus; TD Cowen says BRIUMVI is nearing blockbuster status.
- TG Therapeutics (TGTX) Stock Price & OverviewBackground on BRIUMVI's market-share gains, the subcutaneous program and earlier guidance raises.
About TG Therapeutics, Inc.
TG Therapeutics is a New York-based biotech company whose business centers on BRIUMVI (ublituximab), an anti-CD20 antibody given by IV infusion to treat relapsing forms of multiple sclerosis. It stands out among biotechs as a single-product commercial company: BRIUMVI sales are growing fast, and the company is testing a subcutaneous (under-the-skin) version along with uses in other autoimmune diseases.
How it makes money
Almost all revenue comes from US net sales of BRIUMVI, which were about $595 million in 2025. In the first half of 2026 they ran about 60%+ above the prior year, and the company's 2026 target for total revenue is about $950 million (approximate, company guidance). A small share comes from selling product to, and collecting license income from, its ex-US partner Neuraxpharm, which sells BRIUMVI in the EU, UK and other markets.
What usually moves TGTX
- BRIUMVI quarterly sales vs. guidance
- Competition in the anti-CD20 MS market (Ocrevus, Kesimpta)
- Phase 3 results for subcutaneous BRIUMVI and simpler dosing
- Pipeline expansion into myasthenia gravis and other autoimmune diseases
- Share buybacks and capital allocation
Similar companies
In the Daily Standout
- November 10, 2026: on the shortlist +7.10%